LYTIX — Lytix Biopharma AS Balance Sheet
0.000.00%
Last trade - 00:00- NOK385.41m
- NOK335.35m
- NOK3.99m
Annual balance sheet for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | NAS | NAS | NAS | NAS | NAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12.8 | 28.4 | 197 | 145 | 50.5 |
| Net Total Receivables | 4.64 | 4.17 | 5.68 | 6.74 | 12.8 |
| Total Other Current Assets | |||||
| Total Current Assets | 17.4 | 32.6 | 203 | 152 | 63.3 |
| Net Property, Plant And Equipment | — | — | 2.14 | 1.38 | 0.548 |
| Other Long Term Assets | |||||
| Total Assets | 17.4 | 32.6 | 205 | 153 | 63.9 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.85 | 12.7 | 14.2 | 17.8 | 12.5 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 3.85 | 12.7 | 15.5 | 18.2 | 12.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Other Equity | |||||
| Total Equity | 13.6 | 19.9 | 190 | 135 | 51.3 |
| Total Liabilities & Shareholders' Equity | 17.4 | 32.6 | 205 | 153 | 63.9 |
| Total Common Shares Outstanding |